Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abiraterone acetate - Churchill Pharmaceuticals

Drug Profile

Abiraterone acetate - Churchill Pharmaceuticals

Alternative Names: AAFP; Abiraterone acetate fine particle ; submicron abiraterone acetate; Yonsa

Latest Information Update: 05 Jan 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Churchill Pharmaceuticals
  • Developer Churchill Pharmaceuticals; Institute of Cancer Research; Sun Pharmaceutical Industries
  • Class Androstenols; Antiandrogens; Antineoplastics; Phenanthrenes; Pyridines; Small molecules
  • Mechanism of Action CYP17A1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Prostate cancer

Most Recent Events

  • 01 Dec 2020 Phase-I/II clinical trials in Prostate cancer (Combination therapy, Late-stage disease, Metastatic disease, Hormone refractory, Second-line therapy or greater) in United Kingdom (PO) (NCT04458311)
  • 07 Jul 2020 Institute of Cancer Research in United Kingdom plans the phase I/II ACTIon trial in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease) in Switzerland and United Kingdom (NCT04458311)
  • 08 Jun 2018 Chemical structure information added
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top